Of elucidating

De Bakey Veteran Affairs Medical Center), Michael Ittmann, MD (Baylor College of Medicine and Michael E.

De Bakey Veteran Affairs Medical Center) Co-Investigators: Rao Mandalapu, MD (Baylor College of Medicine), Arun Sreekumar, Ph D (Baylor College of Medicine), Nancy Weigel, Ph D (Baylor College of Medicine), Nora Navone, Ph D (University of Texas MD Anderson Cancer Center), Curtis Pettaway, MD (University of Texas MD Anderson Cancer Center), Cheryl Walker, Ph D (Baylor College of Medicine), Aihua Ed Yen, MD (Baylor College of Medicine), Nicholas Mitsiades, MD (Baylor College of Medicine), Cristian Coarfa, Ph D (Baylor College of Medicine), Nagireddy Putluri, Ph D (Baylor College of Medicine), Zhandong Liu, Ph D (Baylor College of Medicine) Project Title: Clinicopathological Correlation and Molecular Signature Identification and Risk Stratification of Prostate Cancer in African-American U. Veterans, With and Without Exposure to Battlefield Chemicals Description: What this means to patients: Factors such as race and chemical exposures can affect risk for prostate cancer and need to be better understood in order to improve prevention and treatment strategies.

The research interest of our group is focussed on the chemistry of transition metal complexes and their use as catalysts for organic reactions.

We investigate the reactivity of transition metal compounds with the aim of elucidating and understanding the elementary steps of a catalytic cycle.

2017 Movember Foundation – PCF Challenge Award (

De Bakey Veteran Affairs Medical Center), Michael Ittmann, MD (Baylor College of Medicine and Michael E.De Bakey Veteran Affairs Medical Center) Co-Investigators: Rao Mandalapu, MD (Baylor College of Medicine), Arun Sreekumar, Ph D (Baylor College of Medicine), Nancy Weigel, Ph D (Baylor College of Medicine), Nora Navone, Ph D (University of Texas MD Anderson Cancer Center), Curtis Pettaway, MD (University of Texas MD Anderson Cancer Center), Cheryl Walker, Ph D (Baylor College of Medicine), Aihua Ed Yen, MD (Baylor College of Medicine), Nicholas Mitsiades, MD (Baylor College of Medicine), Cristian Coarfa, Ph D (Baylor College of Medicine), Nagireddy Putluri, Ph D (Baylor College of Medicine), Zhandong Liu, Ph D (Baylor College of Medicine) Project Title: Clinicopathological Correlation and Molecular Signature Identification and Risk Stratification of Prostate Cancer in African-American U. Veterans, With and Without Exposure to Battlefield Chemicals Description: What this means to patients: Factors such as race and chemical exposures can affect risk for prostate cancer and need to be better understood in order to improve prevention and treatment strategies.The research interest of our group is focussed on the chemistry of transition metal complexes and their use as catalysts for organic reactions.We investigate the reactivity of transition metal compounds with the aim of elucidating and understanding the elementary steps of a catalytic cycle.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Nupam Mahajan, Ph D (H.Lee Moffitt Cancer Center), Felix Feng, MD (University of California, San Francisco) Co-Investigators: Jonathan Chou, MD (University of California, San Francisco), Kiran Mahajan, Ph D (H.2017 PCF Challenge Award ($1 Million) Award Donor: Stein Erik Hagen Principal Investigators: Shahneen Sandhu, MBBS (University of Melbourne), Rodney Hicks, MD, MBBS (Peter Mac Callum Cancer Centre), Michael Hofman, MBBS (Peter Mac Callum Cancer Centre), Scott Williams, MD, MBBS (Peter Mac Callum Cancer Centre), Carleen Cullinane, Ph D, Sc D (Peter Mac Callum Cancer Centre), John Violet, MBBS, Ph D (Peter Mac Callum Cancer Centre), Paul Neeson, Ph D, Sc D (Peter Mac Callum Cancer Centre) Co-Investigators: David Goode, Ph D, Sc D (Peter Mac Callum Cancer Centre), Lisa Horvath, MBBS, Ph D (Chris O’Brien Lifehouse), Anthony Joshua, MBBS, Ph D (St Vincents Hospital, Kinghorn Cancer Centre), Carmel Pezaro, MBBS, (Monash University), Luc Furic, Ph D, Sc D (Peter Mac Callum Cancer Centre) Project Title: Harnessing Synergies between What this means to patients: Combining targeted radiation therapy with agents that prevent the repair of damaged DNA may be highly effective in the treatment of cancer.This team will conduct clinical trials to test the efficacy of combining a prostate cancer-targeting radiation therapy, Lu-PSMA, with the PARP-inhibitor olaparib, in advanced prostate cancer patients, and will identify mechanisms of action and biomarkers that can be used to select patients most likely to benefit from this treatment.

||

De Bakey Veteran Affairs Medical Center), Michael Ittmann, MD (Baylor College of Medicine and Michael E.

De Bakey Veteran Affairs Medical Center) Co-Investigators: Rao Mandalapu, MD (Baylor College of Medicine), Arun Sreekumar, Ph D (Baylor College of Medicine), Nancy Weigel, Ph D (Baylor College of Medicine), Nora Navone, Ph D (University of Texas MD Anderson Cancer Center), Curtis Pettaway, MD (University of Texas MD Anderson Cancer Center), Cheryl Walker, Ph D (Baylor College of Medicine), Aihua Ed Yen, MD (Baylor College of Medicine), Nicholas Mitsiades, MD (Baylor College of Medicine), Cristian Coarfa, Ph D (Baylor College of Medicine), Nagireddy Putluri, Ph D (Baylor College of Medicine), Zhandong Liu, Ph D (Baylor College of Medicine) Project Title: Clinicopathological Correlation and Molecular Signature Identification and Risk Stratification of Prostate Cancer in African-American U. Veterans, With and Without Exposure to Battlefield Chemicals Description: What this means to patients: Factors such as race and chemical exposures can affect risk for prostate cancer and need to be better understood in order to improve prevention and treatment strategies.

The research interest of our group is focussed on the chemistry of transition metal complexes and their use as catalysts for organic reactions.

We investigate the reactivity of transition metal compounds with the aim of elucidating and understanding the elementary steps of a catalytic cycle.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Nupam Mahajan, Ph D (H.

Lee Moffitt Cancer Center), Felix Feng, MD (University of California, San Francisco) Co-Investigators: Jonathan Chou, MD (University of California, San Francisco), Kiran Mahajan, Ph D (H.

2017 PCF Challenge Award ($1 Million) Award Donor: Stein Erik Hagen Principal Investigators: Shahneen Sandhu, MBBS (University of Melbourne), Rodney Hicks, MD, MBBS (Peter Mac Callum Cancer Centre), Michael Hofman, MBBS (Peter Mac Callum Cancer Centre), Scott Williams, MD, MBBS (Peter Mac Callum Cancer Centre), Carleen Cullinane, Ph D, Sc D (Peter Mac Callum Cancer Centre), John Violet, MBBS, Ph D (Peter Mac Callum Cancer Centre), Paul Neeson, Ph D, Sc D (Peter Mac Callum Cancer Centre) Co-Investigators: David Goode, Ph D, Sc D (Peter Mac Callum Cancer Centre), Lisa Horvath, MBBS, Ph D (Chris O’Brien Lifehouse), Anthony Joshua, MBBS, Ph D (St Vincents Hospital, Kinghorn Cancer Centre), Carmel Pezaro, MBBS, (Monash University), Luc Furic, Ph D, Sc D (Peter Mac Callum Cancer Centre) Project Title: Harnessing Synergies between What this means to patients: Combining targeted radiation therapy with agents that prevent the repair of damaged DNA may be highly effective in the treatment of cancer.

This team will conduct clinical trials to test the efficacy of combining a prostate cancer-targeting radiation therapy, Lu-PSMA, with the PARP-inhibitor olaparib, in advanced prostate cancer patients, and will identify mechanisms of action and biomarkers that can be used to select patients most likely to benefit from this treatment.

Million) Principal Investigators: Nupam Mahajan, Ph D (H.

Lee Moffitt Cancer Center), Felix Feng, MD (University of California, San Francisco) Co-Investigators: Jonathan Chou, MD (University of California, San Francisco), Kiran Mahajan, Ph D (H.

2017 PCF Challenge Award (

De Bakey Veteran Affairs Medical Center), Michael Ittmann, MD (Baylor College of Medicine and Michael E.De Bakey Veteran Affairs Medical Center) Co-Investigators: Rao Mandalapu, MD (Baylor College of Medicine), Arun Sreekumar, Ph D (Baylor College of Medicine), Nancy Weigel, Ph D (Baylor College of Medicine), Nora Navone, Ph D (University of Texas MD Anderson Cancer Center), Curtis Pettaway, MD (University of Texas MD Anderson Cancer Center), Cheryl Walker, Ph D (Baylor College of Medicine), Aihua Ed Yen, MD (Baylor College of Medicine), Nicholas Mitsiades, MD (Baylor College of Medicine), Cristian Coarfa, Ph D (Baylor College of Medicine), Nagireddy Putluri, Ph D (Baylor College of Medicine), Zhandong Liu, Ph D (Baylor College of Medicine) Project Title: Clinicopathological Correlation and Molecular Signature Identification and Risk Stratification of Prostate Cancer in African-American U. Veterans, With and Without Exposure to Battlefield Chemicals Description: What this means to patients: Factors such as race and chemical exposures can affect risk for prostate cancer and need to be better understood in order to improve prevention and treatment strategies.The research interest of our group is focussed on the chemistry of transition metal complexes and their use as catalysts for organic reactions.We investigate the reactivity of transition metal compounds with the aim of elucidating and understanding the elementary steps of a catalytic cycle.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Nupam Mahajan, Ph D (H.Lee Moffitt Cancer Center), Felix Feng, MD (University of California, San Francisco) Co-Investigators: Jonathan Chou, MD (University of California, San Francisco), Kiran Mahajan, Ph D (H.2017 PCF Challenge Award ($1 Million) Award Donor: Stein Erik Hagen Principal Investigators: Shahneen Sandhu, MBBS (University of Melbourne), Rodney Hicks, MD, MBBS (Peter Mac Callum Cancer Centre), Michael Hofman, MBBS (Peter Mac Callum Cancer Centre), Scott Williams, MD, MBBS (Peter Mac Callum Cancer Centre), Carleen Cullinane, Ph D, Sc D (Peter Mac Callum Cancer Centre), John Violet, MBBS, Ph D (Peter Mac Callum Cancer Centre), Paul Neeson, Ph D, Sc D (Peter Mac Callum Cancer Centre) Co-Investigators: David Goode, Ph D, Sc D (Peter Mac Callum Cancer Centre), Lisa Horvath, MBBS, Ph D (Chris O’Brien Lifehouse), Anthony Joshua, MBBS, Ph D (St Vincents Hospital, Kinghorn Cancer Centre), Carmel Pezaro, MBBS, (Monash University), Luc Furic, Ph D, Sc D (Peter Mac Callum Cancer Centre) Project Title: Harnessing Synergies between What this means to patients: Combining targeted radiation therapy with agents that prevent the repair of damaged DNA may be highly effective in the treatment of cancer.This team will conduct clinical trials to test the efficacy of combining a prostate cancer-targeting radiation therapy, Lu-PSMA, with the PARP-inhibitor olaparib, in advanced prostate cancer patients, and will identify mechanisms of action and biomarkers that can be used to select patients most likely to benefit from this treatment.

||

De Bakey Veteran Affairs Medical Center), Michael Ittmann, MD (Baylor College of Medicine and Michael E.

De Bakey Veteran Affairs Medical Center) Co-Investigators: Rao Mandalapu, MD (Baylor College of Medicine), Arun Sreekumar, Ph D (Baylor College of Medicine), Nancy Weigel, Ph D (Baylor College of Medicine), Nora Navone, Ph D (University of Texas MD Anderson Cancer Center), Curtis Pettaway, MD (University of Texas MD Anderson Cancer Center), Cheryl Walker, Ph D (Baylor College of Medicine), Aihua Ed Yen, MD (Baylor College of Medicine), Nicholas Mitsiades, MD (Baylor College of Medicine), Cristian Coarfa, Ph D (Baylor College of Medicine), Nagireddy Putluri, Ph D (Baylor College of Medicine), Zhandong Liu, Ph D (Baylor College of Medicine) Project Title: Clinicopathological Correlation and Molecular Signature Identification and Risk Stratification of Prostate Cancer in African-American U. Veterans, With and Without Exposure to Battlefield Chemicals Description: What this means to patients: Factors such as race and chemical exposures can affect risk for prostate cancer and need to be better understood in order to improve prevention and treatment strategies.

The research interest of our group is focussed on the chemistry of transition metal complexes and their use as catalysts for organic reactions.

We investigate the reactivity of transition metal compounds with the aim of elucidating and understanding the elementary steps of a catalytic cycle.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Nupam Mahajan, Ph D (H.

Lee Moffitt Cancer Center), Felix Feng, MD (University of California, San Francisco) Co-Investigators: Jonathan Chou, MD (University of California, San Francisco), Kiran Mahajan, Ph D (H.

2017 PCF Challenge Award ($1 Million) Award Donor: Stein Erik Hagen Principal Investigators: Shahneen Sandhu, MBBS (University of Melbourne), Rodney Hicks, MD, MBBS (Peter Mac Callum Cancer Centre), Michael Hofman, MBBS (Peter Mac Callum Cancer Centre), Scott Williams, MD, MBBS (Peter Mac Callum Cancer Centre), Carleen Cullinane, Ph D, Sc D (Peter Mac Callum Cancer Centre), John Violet, MBBS, Ph D (Peter Mac Callum Cancer Centre), Paul Neeson, Ph D, Sc D (Peter Mac Callum Cancer Centre) Co-Investigators: David Goode, Ph D, Sc D (Peter Mac Callum Cancer Centre), Lisa Horvath, MBBS, Ph D (Chris O’Brien Lifehouse), Anthony Joshua, MBBS, Ph D (St Vincents Hospital, Kinghorn Cancer Centre), Carmel Pezaro, MBBS, (Monash University), Luc Furic, Ph D, Sc D (Peter Mac Callum Cancer Centre) Project Title: Harnessing Synergies between What this means to patients: Combining targeted radiation therapy with agents that prevent the repair of damaged DNA may be highly effective in the treatment of cancer.

This team will conduct clinical trials to test the efficacy of combining a prostate cancer-targeting radiation therapy, Lu-PSMA, with the PARP-inhibitor olaparib, in advanced prostate cancer patients, and will identify mechanisms of action and biomarkers that can be used to select patients most likely to benefit from this treatment.

Million) Award Donor: Stein Erik Hagen Principal Investigators: Shahneen Sandhu, MBBS (University of Melbourne), Rodney Hicks, MD, MBBS (Peter Mac Callum Cancer Centre), Michael Hofman, MBBS (Peter Mac Callum Cancer Centre), Scott Williams, MD, MBBS (Peter Mac Callum Cancer Centre), Carleen Cullinane, Ph D, Sc D (Peter Mac Callum Cancer Centre), John Violet, MBBS, Ph D (Peter Mac Callum Cancer Centre), Paul Neeson, Ph D, Sc D (Peter Mac Callum Cancer Centre) Co-Investigators: David Goode, Ph D, Sc D (Peter Mac Callum Cancer Centre), Lisa Horvath, MBBS, Ph D (Chris O’Brien Lifehouse), Anthony Joshua, MBBS, Ph D (St Vincents Hospital, Kinghorn Cancer Centre), Carmel Pezaro, MBBS, (Monash University), Luc Furic, Ph D, Sc D (Peter Mac Callum Cancer Centre) Project Title: Harnessing Synergies between What this means to patients: Combining targeted radiation therapy with agents that prevent the repair of damaged DNA may be highly effective in the treatment of cancer.

This team will conduct clinical trials to test the efficacy of combining a prostate cancer-targeting radiation therapy, Lu-PSMA, with the PARP-inhibitor olaparib, in advanced prostate cancer patients, and will identify mechanisms of action and biomarkers that can be used to select patients most likely to benefit from this treatment.

2017 PCF Challenge Award (5,000) Principal Investigators: Alicia Morgans, MD, MPH (Northwestern University), Charles Ryan, MD (University of California, San Francisco) Co-Investigators: Lei Wang, Ph D (Northwestern University), Glenn Heller, Ph D (Memorial Sloan Kettering Cancer Center), Jennifer Yokoyama, Ph D (University of California, San Francisco) Project Title: SEARCH: What this means to patients: Androgen deprivation therapy may increase risk for cognitive disorders in prostate cancer patients.

2017 PCF Challenge Award (

2017 PCF Challenge Award ($515,000) Principal Investigators: Alicia Morgans, MD, MPH (Northwestern University), Charles Ryan, MD (University of California, San Francisco) Co-Investigators: Lei Wang, Ph D (Northwestern University), Glenn Heller, Ph D (Memorial Sloan Kettering Cancer Center), Jennifer Yokoyama, Ph D (University of California, San Francisco) Project Title: SEARCH: What this means to patients: Androgen deprivation therapy may increase risk for cognitive disorders in prostate cancer patients.

2017 PCF Challenge Award ($1 Million) Award Donor: Janssen Pharmaceuticals Principal Investigators: Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Mary-Ellen Taplin, MD (Harvard: Dana-Farber Cancer Institute) Co-Investigators: Wassim Abida, MD, Ph D (Memorial Sloan Kettering Cancer Center), Anuradha Gopalan, MD (Memorial Sloan Kettering Cancer Center), Glenn Heller, Ph D (Memorial Sloan Kettering Cancer Center), Maika Mitchell, Ph D (Memorial Sloan Kettering Cancer Center), Nikolaus Schultz, Ph D (Memorial Sloan Kettering Cancer Center), Steven Balk, MD, Ph D (Harvard: Beth Israel Deaconess Medical Center), Atish Choudhury, MD, Ph D (Harvard: Dana-Farber Cancer Institute), Eliezer Van Allen, MD (Harvard: Dana-Farber Cancer Institute), Adam Kibel, MD (Harvard: Brigham and Women’s Hospital), Huihui Ye, MD, MSc (Harvard: Beth Israel Deaconess Medical Center), Rosina Lis, MD (Harvard: Dana-Farber Cancer Institute), Wai Yi Tsui, MD, Ph D (Memorial Sloan Kettering Cancer Center), Michaela Bowden, Ph D (Harvard: Dana-Farber Cancer Institute), Min Yuen Teo, MD (Memorial Sloan Kettering Cancer Center) Project Title: Curing Lethal Non-Castrate Prostate Cancer: Integrative Molecular Analysis for Mechanisms of Exceptional Response, Resistance and Recurrence Description: What this means to patients: There is currently no curative treatment for men who are diagnosed with metastatic prostate cancer or those who relapse after treatment for primary prostate cancer.

This team will test whether an intense, multimodal treatment strategy can be curative in these patients, and establish biomarkers for identifying the patients who should receive this treatment.

2017 PCF Challenge Award ($1 Million) Award Donor: Stein Erik Hagen Principal Investigators: Johannes Czernin, MD (University of California, Los Angeles), Caius Radu, MD (University of California, Los Angeles) Co-Investigators: Robert Reiter, MD (University of California, Los Angeles), Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles) Project Title: Elucidating mechanisms of effectiveness and resistance to Prostate Specific Membrane Antigen (PSMA) targeted Radioligand Therapy (RLT) using Lu-PSMA-617 in advanced prostate cancer patients, and will identify possible mechanisms of treatment resistance and potential therapeutic targets for combination treatments that may improve patient outcomes.

2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Merkin, Todd Boehly Principal Investigators: Isla Garraway, MD, Ph D (University of California, Los Angeles), Beatrice Knudsen, MD, Ph D (Cedars-Sinai Medical Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles), Stephen Freedland, MD (Cedars-Sinai Medical Center), James Hicks, Ph D (Cold Spring Harbor Laboratory), Sungyong You, Ph D (Cedars-Sinai Medical Center), Arkadiusz Gertych, Ph D (Cedars-Sinai Medical Center), Michael Lewis, MD (Greater Los Angeles Veterans Affairs Healthcare System), Jeremy Shelton, MD (University of California, Los Angeles) Project Title: Multiplatform Profiling of Lethal Prostate Cancer in the Veterans Affairs Population Description: What this means to patients: Increasing our understanding of the biology of metastatic prostate cancer will improve prostate cancer staging, prognosis and treatment.

||

2017 PCF Challenge Award ($515,000) Principal Investigators: Alicia Morgans, MD, MPH (Northwestern University), Charles Ryan, MD (University of California, San Francisco) Co-Investigators: Lei Wang, Ph D (Northwestern University), Glenn Heller, Ph D (Memorial Sloan Kettering Cancer Center), Jennifer Yokoyama, Ph D (University of California, San Francisco) Project Title: SEARCH: What this means to patients: Androgen deprivation therapy may increase risk for cognitive disorders in prostate cancer patients.2017 PCF Challenge Award ($1 Million) Award Donor: Janssen Pharmaceuticals Principal Investigators: Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Mary-Ellen Taplin, MD (Harvard: Dana-Farber Cancer Institute) Co-Investigators: Wassim Abida, MD, Ph D (Memorial Sloan Kettering Cancer Center), Anuradha Gopalan, MD (Memorial Sloan Kettering Cancer Center), Glenn Heller, Ph D (Memorial Sloan Kettering Cancer Center), Maika Mitchell, Ph D (Memorial Sloan Kettering Cancer Center), Nikolaus Schultz, Ph D (Memorial Sloan Kettering Cancer Center), Steven Balk, MD, Ph D (Harvard: Beth Israel Deaconess Medical Center), Atish Choudhury, MD, Ph D (Harvard: Dana-Farber Cancer Institute), Eliezer Van Allen, MD (Harvard: Dana-Farber Cancer Institute), Adam Kibel, MD (Harvard: Brigham and Women’s Hospital), Huihui Ye, MD, MSc (Harvard: Beth Israel Deaconess Medical Center), Rosina Lis, MD (Harvard: Dana-Farber Cancer Institute), Wai Yi Tsui, MD, Ph D (Memorial Sloan Kettering Cancer Center), Michaela Bowden, Ph D (Harvard: Dana-Farber Cancer Institute), Min Yuen Teo, MD (Memorial Sloan Kettering Cancer Center) Project Title: Curing Lethal Non-Castrate Prostate Cancer: Integrative Molecular Analysis for Mechanisms of Exceptional Response, Resistance and Recurrence Description: What this means to patients: There is currently no curative treatment for men who are diagnosed with metastatic prostate cancer or those who relapse after treatment for primary prostate cancer.This team will test whether an intense, multimodal treatment strategy can be curative in these patients, and establish biomarkers for identifying the patients who should receive this treatment.2017 PCF Challenge Award ($1 Million) Award Donor: Stein Erik Hagen Principal Investigators: Johannes Czernin, MD (University of California, Los Angeles), Caius Radu, MD (University of California, Los Angeles) Co-Investigators: Robert Reiter, MD (University of California, Los Angeles), Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles) Project Title: Elucidating mechanisms of effectiveness and resistance to Prostate Specific Membrane Antigen (PSMA) targeted Radioligand Therapy (RLT) using Lu-PSMA-617 in advanced prostate cancer patients, and will identify possible mechanisms of treatment resistance and potential therapeutic targets for combination treatments that may improve patient outcomes.2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Merkin, Todd Boehly Principal Investigators: Isla Garraway, MD, Ph D (University of California, Los Angeles), Beatrice Knudsen, MD, Ph D (Cedars-Sinai Medical Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles), Stephen Freedland, MD (Cedars-Sinai Medical Center), James Hicks, Ph D (Cold Spring Harbor Laboratory), Sungyong You, Ph D (Cedars-Sinai Medical Center), Arkadiusz Gertych, Ph D (Cedars-Sinai Medical Center), Michael Lewis, MD (Greater Los Angeles Veterans Affairs Healthcare System), Jeremy Shelton, MD (University of California, Los Angeles) Project Title: Multiplatform Profiling of Lethal Prostate Cancer in the Veterans Affairs Population Description: What this means to patients: Increasing our understanding of the biology of metastatic prostate cancer will improve prostate cancer staging, prognosis and treatment.

Million) Award Donor: Janssen Pharmaceuticals Principal Investigators: Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Mary-Ellen Taplin, MD (Harvard: Dana-Farber Cancer Institute) Co-Investigators: Wassim Abida, MD, Ph D (Memorial Sloan Kettering Cancer Center), Anuradha Gopalan, MD (Memorial Sloan Kettering Cancer Center), Glenn Heller, Ph D (Memorial Sloan Kettering Cancer Center), Maika Mitchell, Ph D (Memorial Sloan Kettering Cancer Center), Nikolaus Schultz, Ph D (Memorial Sloan Kettering Cancer Center), Steven Balk, MD, Ph D (Harvard: Beth Israel Deaconess Medical Center), Atish Choudhury, MD, Ph D (Harvard: Dana-Farber Cancer Institute), Eliezer Van Allen, MD (Harvard: Dana-Farber Cancer Institute), Adam Kibel, MD (Harvard: Brigham and Women’s Hospital), Huihui Ye, MD, MSc (Harvard: Beth Israel Deaconess Medical Center), Rosina Lis, MD (Harvard: Dana-Farber Cancer Institute), Wai Yi Tsui, MD, Ph D (Memorial Sloan Kettering Cancer Center), Michaela Bowden, Ph D (Harvard: Dana-Farber Cancer Institute), Min Yuen Teo, MD (Memorial Sloan Kettering Cancer Center) Project Title: Curing Lethal Non-Castrate Prostate Cancer: Integrative Molecular Analysis for Mechanisms of Exceptional Response, Resistance and Recurrence Description: What this means to patients: There is currently no curative treatment for men who are diagnosed with metastatic prostate cancer or those who relapse after treatment for primary prostate cancer.

This team will test whether an intense, multimodal treatment strategy can be curative in these patients, and establish biomarkers for identifying the patients who should receive this treatment.

2017 PCF Challenge Award (

2017 PCF Challenge Award ($515,000) Principal Investigators: Alicia Morgans, MD, MPH (Northwestern University), Charles Ryan, MD (University of California, San Francisco) Co-Investigators: Lei Wang, Ph D (Northwestern University), Glenn Heller, Ph D (Memorial Sloan Kettering Cancer Center), Jennifer Yokoyama, Ph D (University of California, San Francisco) Project Title: SEARCH: What this means to patients: Androgen deprivation therapy may increase risk for cognitive disorders in prostate cancer patients.

2017 PCF Challenge Award ($1 Million) Award Donor: Janssen Pharmaceuticals Principal Investigators: Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Mary-Ellen Taplin, MD (Harvard: Dana-Farber Cancer Institute) Co-Investigators: Wassim Abida, MD, Ph D (Memorial Sloan Kettering Cancer Center), Anuradha Gopalan, MD (Memorial Sloan Kettering Cancer Center), Glenn Heller, Ph D (Memorial Sloan Kettering Cancer Center), Maika Mitchell, Ph D (Memorial Sloan Kettering Cancer Center), Nikolaus Schultz, Ph D (Memorial Sloan Kettering Cancer Center), Steven Balk, MD, Ph D (Harvard: Beth Israel Deaconess Medical Center), Atish Choudhury, MD, Ph D (Harvard: Dana-Farber Cancer Institute), Eliezer Van Allen, MD (Harvard: Dana-Farber Cancer Institute), Adam Kibel, MD (Harvard: Brigham and Women’s Hospital), Huihui Ye, MD, MSc (Harvard: Beth Israel Deaconess Medical Center), Rosina Lis, MD (Harvard: Dana-Farber Cancer Institute), Wai Yi Tsui, MD, Ph D (Memorial Sloan Kettering Cancer Center), Michaela Bowden, Ph D (Harvard: Dana-Farber Cancer Institute), Min Yuen Teo, MD (Memorial Sloan Kettering Cancer Center) Project Title: Curing Lethal Non-Castrate Prostate Cancer: Integrative Molecular Analysis for Mechanisms of Exceptional Response, Resistance and Recurrence Description: What this means to patients: There is currently no curative treatment for men who are diagnosed with metastatic prostate cancer or those who relapse after treatment for primary prostate cancer.

This team will test whether an intense, multimodal treatment strategy can be curative in these patients, and establish biomarkers for identifying the patients who should receive this treatment.

2017 PCF Challenge Award ($1 Million) Award Donor: Stein Erik Hagen Principal Investigators: Johannes Czernin, MD (University of California, Los Angeles), Caius Radu, MD (University of California, Los Angeles) Co-Investigators: Robert Reiter, MD (University of California, Los Angeles), Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles) Project Title: Elucidating mechanisms of effectiveness and resistance to Prostate Specific Membrane Antigen (PSMA) targeted Radioligand Therapy (RLT) using Lu-PSMA-617 in advanced prostate cancer patients, and will identify possible mechanisms of treatment resistance and potential therapeutic targets for combination treatments that may improve patient outcomes.

2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Merkin, Todd Boehly Principal Investigators: Isla Garraway, MD, Ph D (University of California, Los Angeles), Beatrice Knudsen, MD, Ph D (Cedars-Sinai Medical Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles), Stephen Freedland, MD (Cedars-Sinai Medical Center), James Hicks, Ph D (Cold Spring Harbor Laboratory), Sungyong You, Ph D (Cedars-Sinai Medical Center), Arkadiusz Gertych, Ph D (Cedars-Sinai Medical Center), Michael Lewis, MD (Greater Los Angeles Veterans Affairs Healthcare System), Jeremy Shelton, MD (University of California, Los Angeles) Project Title: Multiplatform Profiling of Lethal Prostate Cancer in the Veterans Affairs Population Description: What this means to patients: Increasing our understanding of the biology of metastatic prostate cancer will improve prostate cancer staging, prognosis and treatment.

||

2017 PCF Challenge Award ($515,000) Principal Investigators: Alicia Morgans, MD, MPH (Northwestern University), Charles Ryan, MD (University of California, San Francisco) Co-Investigators: Lei Wang, Ph D (Northwestern University), Glenn Heller, Ph D (Memorial Sloan Kettering Cancer Center), Jennifer Yokoyama, Ph D (University of California, San Francisco) Project Title: SEARCH: What this means to patients: Androgen deprivation therapy may increase risk for cognitive disorders in prostate cancer patients.2017 PCF Challenge Award ($1 Million) Award Donor: Janssen Pharmaceuticals Principal Investigators: Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Mary-Ellen Taplin, MD (Harvard: Dana-Farber Cancer Institute) Co-Investigators: Wassim Abida, MD, Ph D (Memorial Sloan Kettering Cancer Center), Anuradha Gopalan, MD (Memorial Sloan Kettering Cancer Center), Glenn Heller, Ph D (Memorial Sloan Kettering Cancer Center), Maika Mitchell, Ph D (Memorial Sloan Kettering Cancer Center), Nikolaus Schultz, Ph D (Memorial Sloan Kettering Cancer Center), Steven Balk, MD, Ph D (Harvard: Beth Israel Deaconess Medical Center), Atish Choudhury, MD, Ph D (Harvard: Dana-Farber Cancer Institute), Eliezer Van Allen, MD (Harvard: Dana-Farber Cancer Institute), Adam Kibel, MD (Harvard: Brigham and Women’s Hospital), Huihui Ye, MD, MSc (Harvard: Beth Israel Deaconess Medical Center), Rosina Lis, MD (Harvard: Dana-Farber Cancer Institute), Wai Yi Tsui, MD, Ph D (Memorial Sloan Kettering Cancer Center), Michaela Bowden, Ph D (Harvard: Dana-Farber Cancer Institute), Min Yuen Teo, MD (Memorial Sloan Kettering Cancer Center) Project Title: Curing Lethal Non-Castrate Prostate Cancer: Integrative Molecular Analysis for Mechanisms of Exceptional Response, Resistance and Recurrence Description: What this means to patients: There is currently no curative treatment for men who are diagnosed with metastatic prostate cancer or those who relapse after treatment for primary prostate cancer.This team will test whether an intense, multimodal treatment strategy can be curative in these patients, and establish biomarkers for identifying the patients who should receive this treatment.2017 PCF Challenge Award ($1 Million) Award Donor: Stein Erik Hagen Principal Investigators: Johannes Czernin, MD (University of California, Los Angeles), Caius Radu, MD (University of California, Los Angeles) Co-Investigators: Robert Reiter, MD (University of California, Los Angeles), Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles) Project Title: Elucidating mechanisms of effectiveness and resistance to Prostate Specific Membrane Antigen (PSMA) targeted Radioligand Therapy (RLT) using Lu-PSMA-617 in advanced prostate cancer patients, and will identify possible mechanisms of treatment resistance and potential therapeutic targets for combination treatments that may improve patient outcomes.2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Merkin, Todd Boehly Principal Investigators: Isla Garraway, MD, Ph D (University of California, Los Angeles), Beatrice Knudsen, MD, Ph D (Cedars-Sinai Medical Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles), Stephen Freedland, MD (Cedars-Sinai Medical Center), James Hicks, Ph D (Cold Spring Harbor Laboratory), Sungyong You, Ph D (Cedars-Sinai Medical Center), Arkadiusz Gertych, Ph D (Cedars-Sinai Medical Center), Michael Lewis, MD (Greater Los Angeles Veterans Affairs Healthcare System), Jeremy Shelton, MD (University of California, Los Angeles) Project Title: Multiplatform Profiling of Lethal Prostate Cancer in the Veterans Affairs Population Description: What this means to patients: Increasing our understanding of the biology of metastatic prostate cancer will improve prostate cancer staging, prognosis and treatment.

Million) Award Donor: Stein Erik Hagen Principal Investigators: Johannes Czernin, MD (University of California, Los Angeles), Caius Radu, MD (University of California, Los Angeles) Co-Investigators: Robert Reiter, MD (University of California, Los Angeles), Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles) Project Title: Elucidating mechanisms of effectiveness and resistance to Prostate Specific Membrane Antigen (PSMA) targeted Radioligand Therapy (RLT) using Lu-PSMA-617 in advanced prostate cancer patients, and will identify possible mechanisms of treatment resistance and potential therapeutic targets for combination treatments that may improve patient outcomes.

2017 PCF VALOR Challenge Award (

2017 PCF Challenge Award ($515,000) Principal Investigators: Alicia Morgans, MD, MPH (Northwestern University), Charles Ryan, MD (University of California, San Francisco) Co-Investigators: Lei Wang, Ph D (Northwestern University), Glenn Heller, Ph D (Memorial Sloan Kettering Cancer Center), Jennifer Yokoyama, Ph D (University of California, San Francisco) Project Title: SEARCH: What this means to patients: Androgen deprivation therapy may increase risk for cognitive disorders in prostate cancer patients.

2017 PCF Challenge Award ($1 Million) Award Donor: Janssen Pharmaceuticals Principal Investigators: Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Mary-Ellen Taplin, MD (Harvard: Dana-Farber Cancer Institute) Co-Investigators: Wassim Abida, MD, Ph D (Memorial Sloan Kettering Cancer Center), Anuradha Gopalan, MD (Memorial Sloan Kettering Cancer Center), Glenn Heller, Ph D (Memorial Sloan Kettering Cancer Center), Maika Mitchell, Ph D (Memorial Sloan Kettering Cancer Center), Nikolaus Schultz, Ph D (Memorial Sloan Kettering Cancer Center), Steven Balk, MD, Ph D (Harvard: Beth Israel Deaconess Medical Center), Atish Choudhury, MD, Ph D (Harvard: Dana-Farber Cancer Institute), Eliezer Van Allen, MD (Harvard: Dana-Farber Cancer Institute), Adam Kibel, MD (Harvard: Brigham and Women’s Hospital), Huihui Ye, MD, MSc (Harvard: Beth Israel Deaconess Medical Center), Rosina Lis, MD (Harvard: Dana-Farber Cancer Institute), Wai Yi Tsui, MD, Ph D (Memorial Sloan Kettering Cancer Center), Michaela Bowden, Ph D (Harvard: Dana-Farber Cancer Institute), Min Yuen Teo, MD (Memorial Sloan Kettering Cancer Center) Project Title: Curing Lethal Non-Castrate Prostate Cancer: Integrative Molecular Analysis for Mechanisms of Exceptional Response, Resistance and Recurrence Description: What this means to patients: There is currently no curative treatment for men who are diagnosed with metastatic prostate cancer or those who relapse after treatment for primary prostate cancer.

This team will test whether an intense, multimodal treatment strategy can be curative in these patients, and establish biomarkers for identifying the patients who should receive this treatment.

2017 PCF Challenge Award ($1 Million) Award Donor: Stein Erik Hagen Principal Investigators: Johannes Czernin, MD (University of California, Los Angeles), Caius Radu, MD (University of California, Los Angeles) Co-Investigators: Robert Reiter, MD (University of California, Los Angeles), Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles) Project Title: Elucidating mechanisms of effectiveness and resistance to Prostate Specific Membrane Antigen (PSMA) targeted Radioligand Therapy (RLT) using Lu-PSMA-617 in advanced prostate cancer patients, and will identify possible mechanisms of treatment resistance and potential therapeutic targets for combination treatments that may improve patient outcomes.

2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Merkin, Todd Boehly Principal Investigators: Isla Garraway, MD, Ph D (University of California, Los Angeles), Beatrice Knudsen, MD, Ph D (Cedars-Sinai Medical Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles), Stephen Freedland, MD (Cedars-Sinai Medical Center), James Hicks, Ph D (Cold Spring Harbor Laboratory), Sungyong You, Ph D (Cedars-Sinai Medical Center), Arkadiusz Gertych, Ph D (Cedars-Sinai Medical Center), Michael Lewis, MD (Greater Los Angeles Veterans Affairs Healthcare System), Jeremy Shelton, MD (University of California, Los Angeles) Project Title: Multiplatform Profiling of Lethal Prostate Cancer in the Veterans Affairs Population Description: What this means to patients: Increasing our understanding of the biology of metastatic prostate cancer will improve prostate cancer staging, prognosis and treatment.

||

2017 PCF Challenge Award ($515,000) Principal Investigators: Alicia Morgans, MD, MPH (Northwestern University), Charles Ryan, MD (University of California, San Francisco) Co-Investigators: Lei Wang, Ph D (Northwestern University), Glenn Heller, Ph D (Memorial Sloan Kettering Cancer Center), Jennifer Yokoyama, Ph D (University of California, San Francisco) Project Title: SEARCH: What this means to patients: Androgen deprivation therapy may increase risk for cognitive disorders in prostate cancer patients.2017 PCF Challenge Award ($1 Million) Award Donor: Janssen Pharmaceuticals Principal Investigators: Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Mary-Ellen Taplin, MD (Harvard: Dana-Farber Cancer Institute) Co-Investigators: Wassim Abida, MD, Ph D (Memorial Sloan Kettering Cancer Center), Anuradha Gopalan, MD (Memorial Sloan Kettering Cancer Center), Glenn Heller, Ph D (Memorial Sloan Kettering Cancer Center), Maika Mitchell, Ph D (Memorial Sloan Kettering Cancer Center), Nikolaus Schultz, Ph D (Memorial Sloan Kettering Cancer Center), Steven Balk, MD, Ph D (Harvard: Beth Israel Deaconess Medical Center), Atish Choudhury, MD, Ph D (Harvard: Dana-Farber Cancer Institute), Eliezer Van Allen, MD (Harvard: Dana-Farber Cancer Institute), Adam Kibel, MD (Harvard: Brigham and Women’s Hospital), Huihui Ye, MD, MSc (Harvard: Beth Israel Deaconess Medical Center), Rosina Lis, MD (Harvard: Dana-Farber Cancer Institute), Wai Yi Tsui, MD, Ph D (Memorial Sloan Kettering Cancer Center), Michaela Bowden, Ph D (Harvard: Dana-Farber Cancer Institute), Min Yuen Teo, MD (Memorial Sloan Kettering Cancer Center) Project Title: Curing Lethal Non-Castrate Prostate Cancer: Integrative Molecular Analysis for Mechanisms of Exceptional Response, Resistance and Recurrence Description: What this means to patients: There is currently no curative treatment for men who are diagnosed with metastatic prostate cancer or those who relapse after treatment for primary prostate cancer.This team will test whether an intense, multimodal treatment strategy can be curative in these patients, and establish biomarkers for identifying the patients who should receive this treatment.2017 PCF Challenge Award ($1 Million) Award Donor: Stein Erik Hagen Principal Investigators: Johannes Czernin, MD (University of California, Los Angeles), Caius Radu, MD (University of California, Los Angeles) Co-Investigators: Robert Reiter, MD (University of California, Los Angeles), Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles) Project Title: Elucidating mechanisms of effectiveness and resistance to Prostate Specific Membrane Antigen (PSMA) targeted Radioligand Therapy (RLT) using Lu-PSMA-617 in advanced prostate cancer patients, and will identify possible mechanisms of treatment resistance and potential therapeutic targets for combination treatments that may improve patient outcomes.2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Merkin, Todd Boehly Principal Investigators: Isla Garraway, MD, Ph D (University of California, Los Angeles), Beatrice Knudsen, MD, Ph D (Cedars-Sinai Medical Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles), Stephen Freedland, MD (Cedars-Sinai Medical Center), James Hicks, Ph D (Cold Spring Harbor Laboratory), Sungyong You, Ph D (Cedars-Sinai Medical Center), Arkadiusz Gertych, Ph D (Cedars-Sinai Medical Center), Michael Lewis, MD (Greater Los Angeles Veterans Affairs Healthcare System), Jeremy Shelton, MD (University of California, Los Angeles) Project Title: Multiplatform Profiling of Lethal Prostate Cancer in the Veterans Affairs Population Description: What this means to patients: Increasing our understanding of the biology of metastatic prostate cancer will improve prostate cancer staging, prognosis and treatment.

Million) Award Donors: Richard Merkin, Todd Boehly Principal Investigators: Isla Garraway, MD, Ph D (University of California, Los Angeles), Beatrice Knudsen, MD, Ph D (Cedars-Sinai Medical Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles), Stephen Freedland, MD (Cedars-Sinai Medical Center), James Hicks, Ph D (Cold Spring Harbor Laboratory), Sungyong You, Ph D (Cedars-Sinai Medical Center), Arkadiusz Gertych, Ph D (Cedars-Sinai Medical Center), Michael Lewis, MD (Greater Los Angeles Veterans Affairs Healthcare System), Jeremy Shelton, MD (University of California, Los Angeles) Project Title: Multiplatform Profiling of Lethal Prostate Cancer in the Veterans Affairs Population Description: What this means to patients: Increasing our understanding of the biology of metastatic prostate cancer will improve prostate cancer staging, prognosis and treatment.

Leave a Reply

  1. nodatingtime com 21-Mar-2020 15:42

    Their accredited installers and service companies send new and unexperienced so-called technicians everytime that obviously know nothing but their go-to solution to every problem of reprocessing (of freon) and electronic board replacement -which cost so much money for a duration that lasts just about the time the warranty of the “repair” expires.